Clinical Trial Update: Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial of rituximab, gemcitabine, and vinorelbine for Hodgkin lymphoma that relapsed or did not respond to prior therapy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Gemzar (gemcitabine)
• Navelbine (vinorelbine)
• Rituxan (rituximab)

Snippet

Sponsor: University of Miami | Conditions: Lymphoma | Phase 2 | Status: WITHDRAWN